

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)

Authors/Task Force Members: Francesco Cosentino* (ESC Chairperson) (Sweden), **Peter J. Grant*** (EASD Chairperson) (United Kingdom), **Victor Aboyans** (France), **Clifford J. Bailey¹** (United Kingdom), **Antonio Ceriello¹** (Italy), **Victoria Delgado** (Netherlands), **Massimo Federici¹** (Italy), **Gerasimos Filippatos** (Greece), **Diederick E. Grobbee** (Netherlands), **Tina Birgitte Hansen** (Denmark), **Heikki V. Huikuri** (Finland), **Isabelle Johansson** (Sweden), **Peter Jüni** (Canada), **Maddalena Lettino** (Italy), **Nikolaus Marx** (Germany), **Linda G. Mellbin** (Sweden), **Carl J. Östgren** (Sweden), **Bianca Rocca** (Italy), **Marco Roffi** (Switzerland), **Naveed Sattar¹** (United Kingdom), **Petar M. Seferović** (Serbia), **Miguel Sousa-Uva** (Portugal), **Paul Valensi** (France), and **David C. Wheeler¹** (United Kingdom)

*Corresponding authors: Francesco Cosentino, Cardiology Unit, Department of Medicine Solna, Karolinska Institute and Karolinska University Hospital, Solna, 171 76 Stockholm, Sweden. Tel: +46 8 517 72 245; Fax: +46 8 34 49 64, Email: francesco.cosentino@ki.se. Peter J. Grant, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds/Leeds Teaching Hospitals NHS Trust, LIGHT Laboratories, Clarendon Way, Leeds LS2 9JT, UK. Tel: +44 44 113 343 7721, Email: p.j.grant@leeds.ac.uk

Authors/Task Force Member Affiliations: listed in the Appendix.

ESC Committee for Practice Guidelines (CPG) and National Cardiac Societies document reviewers: listed in the Appendix.

¹Representing the EASD.

ESC entities having participated in the development of this document:

Associations: Acute Cardiovascular Care Association (ACCA), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).

Councils: Council on Cardiovascular Primary Care, Council on Hypertension.

Working Groups: Aorta and Peripheral Vascular Diseases, Cardiovascular Surgery, Thrombosis.

The content of these ESC Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the *European Heart Journal* and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oxfordjournals.org).

Disclaimer: The Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The ESC and EASD are not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

© The European Society of Cardiology 2019. All rights reserved. For permissions please email: journals.permissions@oup.com

Document Reviewers: Massimo Francesco Piepoli (ESC Review Coordinator) (Italy), Kåre I. Birkeland¹ (EASD Review Coordinator) (Norway), Stamatis Adamopoulos (Greece), Ramzi Ajjan (United Kingdom), Angelo Avogaro (Italy), Colin Baigent (United Kingdom), Marianne Brodmann (Austria), Héctor Bueno (Spain), Claudio Ceconi (Italy), Ovidiu Chioncel (Romania), Andrew Coats (United Kingdom), Jean-Philippe Collet (France), Peter Collins (United Kingdom), Bernard Cosyns (Belgium), Carlo Di Mario (Italy), Miles Fisher¹ (United Kingdom), Donna Fitzsimons (United Kingdom), Sigrun Halvorsen (Norway), Dominique Hansen (Belgium), Arno Hoes (Netherlands), Richard I. G. Holt¹ (United Kingdom), Philip Home¹ (United Kingdom), Hugo A. Katus (Germany), Kamlesh Khunti (United Kingdom), Michel Komajda (France), Ekaterini Lambrinou (Cyprus), Ulf Landmesser (Germany), Basil S. Lewis (Israel), Cecilia Linde (Sweden), Roberto Lorusso (Netherlands), François Mach (Switzerland), Christian Mueller (Switzerland), Franz-Josef Neumann (Germany), Frederik Persson¹ (Denmark), Steffen E. Petersen (United Kingdom), Anna Sonia Petronio (Italy), Dimitrios J. Richter (Greece), Giuseppe M. C. Rosano (Italy/United Kingdom), Peter Rossing¹ (Denmark), Lars Rydén (Sweden), Evgeny Shlyakhto (Russian Federation), Iain A. Simpson (United Kingdom), Rhian M. Touyz (United Kingdom), William Wijns (Ireland), Matthias Wilhelm (Switzerland), Bryan Williams (United Kingdom)

The disclosure forms of all experts involved in the development of these Guidelines are available on the ESC website www.escardio.org/guidelines

 **Click here to access the corresponding chapter in ESC CardioMed - Section 19 Diabetes mellitus and metabolic syndrome**

Online publish-ahead-of-print 31 August 2019

Keywords

Guidelines • diabetes mellitus • impaired glucose tolerance • cardiovascular diseases • epidemiology • risk factors • prevention • cardiovascular risk assessment • patient management • pharmacological treatment • revascularization • patient-centred care

Table of contents

Abbreviations and acronyms	258	6.1.1.4 Vegetables, legumes, fruits, and wholegrain cereals	271
1 Preamble	260	6.1.1.5 Alcohol consumption	271
2 Introduction	262	6.1.1.6 Coffee and tea	271
3 What is new in the 2019 Guidelines?	263	6.1.1.7 Vitamins and macronutrients	271
4 Diagnosis of diabetes and pre-diabetes	265	6.1.2 Physical activity	272
5 Cardiovascular risk assessment in patients with diabetes and pre-diabetes	266	6.1.3 Smoking	272
5.1 Diabetes, pre-diabetes, and cardiovascular risk	266	6.2 Glucose	272
5.2 Stratification of cardiovascular risk in individuals with diabetes	267	6.2.1 Glycaemic targets	272
5.3 Stratification of cardiovascular risk in individuals with pre-diabetes	267	6.2.1.1 Additional glucose targets	272
5.4 Clinical assessment of cardiovascular damage	267	6.2.2 Glucose-lowering agents	273
5.4.1 Biomarkers	267	6.2.3 Special considerations	273
5.4.2 Electrocardiography	268	6.2.3.1 Hypoglycaemia	273
5.4.3 Imaging techniques	268	6.2.3.2 Glucose monitoring	273
6 Prevention of cardiovascular disease in patients with diabetes and pre-diabetes	271	6.3 Blood pressure	274
6.1 Lifestyle	271	6.3.1 Treatment targets	274
6.1.1 Diet	271	6.3.2 Management of blood pressure lowering	274
6.1.1.1 Carbohydrate	271	6.3.2.1 Effects of lifestyle intervention and weight loss	274
6.1.1.2 Fats	271	6.3.2.2 Pharmacological treatments	274
6.1.1.3 Proteins	271	6.3.2.3 Blood pressure changes with glucose-lowering treatments	274
		6.4 Lipids	275
		6.4.1 Lipid-lowering agents	275
		6.4.1.1 Statins	275
		6.4.1.2 Ezetimibe	276
		6.4.1.3 Proprotein convertase subtilisin/kexin type 9	276

6.4.1.4 Fibrates 276

6.5 Platelets 277

6.5.1 Aspirin 277

6.5.1.1 Primary prevention 278

6.5.1.2 Secondary prevention 278

6.6 Multifactorial approaches 278

6.6.1 Principles of multifactorial management 278

7 Management of coronary artery disease 280

7.1 Medical treatment 280

7.1.1 Effects of intensified glucose control 280

7.1.1.1 UKPDS 280

7.1.1.2 ACCORD, ADVANCE, and VADT 280

7.1.1.3 DIGAMI 1 and 2 280

7.1.2 Glucose-lowering agents: new evidence from cardiovascular outcome trials 281

7.1.2.1 Established oral glucose-lowering drugs 281

7.1.2.2 Newer oral glucose-lowering drugs 281

7.1.2.3 Implications of recent cardiovascular outcome trials 283

7.1.3 Specific cardiovascular therapies 286

7.1.3.1 Beta-blockers 286

7.1.3.2 Blockers of the renin–angiotensin–aldosterone system 286

7.1.3.3 Lipid-lowering drugs 286

7.1.3.4 Nitrates and calcium channel blockers 286

7.1.3.5 Other anti-ischaemic drugs 286

7.1.3.6 Antiplatelet and antithrombotic drugs (see section 6.5) .. 287

7.2 Revascularization 288

7.2.1 Percutaneous coronary intervention vs. coronary artery bypass graft surgery 288

7.2.2 Adjunctive pharmacotherapy 289

8 Heart failure and diabetes 290

8.1 Prognostic implications of diabetes mellitus in heart failure ... 291

8.2 Mechanisms of left ventricular dysfunction in diabetes mellitus 291

8.3 Phenotypes of left ventricular dysfunction in diabetes mellitus 292

8.4 Treatment of heart failure in diabetes mellitus 292

8.4.1 Renin-angiotensin-aldosterone system and a neprilysin inhibitors 292

8.4.2 Beta-blockers 292

8.4.3 Ivabradine 292

8.4.4 Digoxin 292

8.4.5 Diuretics 292

8.4.6 Device therapy and surgery 292

8.5 Effect of oral glucose-lowering agents on heart failure 292

8.5.1 Metformin 292

8.5.2 Sulfonylureas 292

8.5.3 Thiazolidinediones 292

8.5.4 Dipeptidyl peptidase-4 inhibitors 292

8.5.5 Glucagon-like peptide-1 receptor agonists 292

8.5.6 Sodium-glucose co-transporter 2 inhibitors 292

9 Arrhythmias: atrial fibrillation, ventricular arrhythmias, and sudden cardiac death 294

9.1 Atrial fibrillation 294

9.1.1 Diabetes and risk of stroke in atrial fibrillation 294

9.2 Ventricular arrhythmias and sudden cardiac death 294

9.2.1 Ventricular premature beats and paroxysmal ventricular tachycardia 294

9.2.2 Sustained ventricular arrhythmias 294

9.2.3 Sudden cardiac death in diabetes 294

10 Aortic and peripheral arterial diseases 295

10.1 Aortic disease 295

10.2 Lower extremity arterial disease 295

10.2.1 Epidemiology and natural history 296

10.2.2 Screening and diagnosis 296

10.2.3 Management of lower extremity artery disease in diabetes 297

10.3 Carotid artery disease 297

11 Chronic kidney disease in diabetes 299

11.1 Management 299

11.1.1 Glycaemic control 299

11.1.2 New approaches to renoprotection 299

12 Patient-centred care 300

12.1 General aspects 300

13 'What to do' and 'what not to do' messages from the Guidelines .. 302

14 Appendix 305

15 References 306

Recommendations

Recommendations for the diagnosis of disorders of glucose metabolism 266

Recommendations for the use of laboratory, electrocardiogram, and imaging testing for cardiovascular risk assessment in asymptomatic patients with diabetes 270

Recommendations for lifestyle modifications for patients with diabetes mellitus and pre-diabetes 272

Recommendations for glycaemic control in individuals with diabetes 273

Recommendations for the management of blood pressure in patients with diabetes and pre-diabetes 275

Recommendations for the management of dyslipidaemia with lipid-lowering drugs 277

Recommendations for the use of antiplatelet therapy in primary prevention in patients with diabetes 278

Recommendations for multifactorial management of patients with diabetes 280

Recommendations for glucose-lowering treatment for patients with diabetes 286

Recommendations for the management of patients with diabetes and acute or chronic coronary syndromes 287

Recommendations for coronary revascularization in patients with diabetes 289

Recommendations for the type of revascularization in patients with diabetes with stable coronary artery disease, suitable coronary anatomy for both procedures, and low predicted surgical mortality 290

Recommendations for the treatment of heart failure in patients with diabetes 293

Recommendations for the treatment of patients with type 2 diabetes to reduce heart failure risk 293

Recommendations for the management of arrhythmias in patients with diabetes 295

Recommendations for the diagnosis and management of peripheral artery disease in patients with diabetes 299

Recommendations for the prevention and management of chronic kidney disease in patients with diabetes	300
Recommendations for patient-centred care of individuals with diabetes	301

List of tables

Table 1 Classes of recommendations	261
Table 2 Levels of evidence	261
Table 3 What is new in the 2019 Guidelines?	263
Table 4 New recommendations in the 2019 Guidelines	264
Table 5 Revised concepts in the 2019 Guidelines	265
Table 6 Diagnostic criteria for diabetes mellitus and pre-diabetes according to the 2006/2011 World Health Organization and 2019 American Diabetes Association recommendations	266
Table 7 Cardiovascular risk categories in patients with diabetes	268
Table 8 Overview of randomized controlled trials	269
Table 9 Summary of treatment targets for the management of patients with diabetes	279
Table 10 Patient characteristics of cardiovascular safety studies with glucose-lowering agents	284
Table 11 Heart failure phenotypes	291
Table 12 Assessment of the risk of amputation: the Wound, Ischaemia, and foot Infection classification	297
Table 13 Chronic kidney disease classification by estimated glomerular filtration rate and albuminuria	299

List of figures

Figure 1 Hazard ratios for vascular outcomes in people with vs. without diabetes mellitus at baseline, based on analyses of 530 083 patients	267
Figure 2 Hazard ratios for coronary heart disease by clinically defined categories of baseline fasting blood glucose concentration	268
Figure 3 Treatment algorithm in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease, or high/very high CV risk	285
Figure 4 Recommendations for coronary revascularization.	291
Figure 5 Screening for lower extremity artery disease in patients with diabetes mellitus.	296

Abbreviations and acronyms

2hPG	2 h plasma glucose
ABI	Ankle–brachial index
ABPM	Ambulatory blood pressure monitoring
ACCORD	Action to Control Cardiovascular Risk in Diabetes
ACE	Acarbose Cardiovascular Evaluation
ACEI	Angiotensin-converting enzyme inhibitor
ACS	Acute coronary syndrome
ADA	American Diabetes Association
ADVANCE	Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation

ADDITION	Anglo-Danish-Dutch Study of Intensive Treatment In People with Screen Detected Diabetes in Primary Care
ADOPT	A Diabetes Outcome Progression Trial
AF	Atrial fibrillation
ARB	Angiotensin receptor blocker
ART	Arterial Revascularization Trial
ASCEND	A Study of Cardiovascular Events in Diabetes
ASCVD	Atherosclerotic cardiovascular disease
ATLAS-ACS TIMI 51	Anti-Xa Therapy to Lower cardiovascular events in Addition to Standard therapy in subjects with Acute Coronary Syndromes - Thrombolysis In Myocardial Infarction 51
BARI 2D	Bypass Angioplasty Revascularization Investigation 2 Diabetes
BEST	Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery Disease
b.i.d.	Twice a day (bis in die)
BIMA	Bilateral internal mammary artery
BMS	Bare-metal stent
BP	Blood pressure
b.p.m.	Beats per minute
CABG	Coronary artery bypass graft
CAC	Coronary artery calcium
CAD	Coronary artery disease
CANVAS	Canagliflozin Cardiovascular Assessment Study
CARDia	Coronary Artery Revascularization in Diabetes
CARMELINA	Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus
CAROLINA	Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
CCS	Chronic coronary syndrome
CE	Cardiac event
CHA ₂ DS ₂ -VASc	Congestive heart failure, Hypertension, Age ≥75 years (Doubled), Diabetes mellitus, Stroke or transient ischaemic attack (Doubled), Vascular disease, Age 65–74 years, Sex category
CHARISMA	Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance
CHARM	Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity
CHD	Coronary heart disease
CI	Confidence interval
CKD	Chronic kidney disease
CLTI	Chronic limb-threatening ischaemia

COMPASS	Cardiovascular Outcomes for People Using Anticoagulation Strategies	EXCEL	Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization trial
CPG	Committee for Practice Guidelines	EXAMINE	Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care
CREDESCENCE	Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation	EXSCEL	Exenatide Study of Cardiovascular Event Lowering
CREST	Carotid Revascularization Endarterectomy versus Stenting Trial	FACTOR-64	Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64
CRT	Cardiac resynchronization therapy	FIELD	Fenofibrate Intervention and Event Lowering in Diabetes
CRT-D	Cardiac resynchronization therapy with an implantable defibrillator	FOURIER	Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk
CT	Computed tomography	FPG	Fasting plasma glucose
CTCA	Computed tomography coronary angiography	FREEDOM	Future Revascularization Evaluation in Patients with Diabetes Mellitus
CV	Cardiovascular	GAMI	Glucose Abnormalities in Patients with Myocardial Infarction
CVD	Cardiovascular disease	GLP1-RA Harmony Outcomes	Glucagon-like peptide-1 receptor agonist Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease
CVOT	Cardiovascular outcome trial	HAS-BLED	Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly
CVRF	Cardiovascular risk factor	HbA1c	Haemoglobin A1c
DADDY-D	Does coronary Atherosclerosis Deserve to be Diagnosed early in Diabetic patients?	HEART2D	Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus
DAPT	Dual antiplatelet therapy	HDL-C	High-density lipoprotein cholesterol
DBP	Diastolic blood pressure	HF	Heart failure
DCCT	Diabetes Control and Complications Trial	HFmrEF	Heart failure with mid-range ejection fraction
DECLARE-TIMI 58	Dapagliflozin Effect on Cardiovascular Events-Thrombolysis In Myocardial Infarction 58 trial	HFpEF	Heart failure with preserved ejection fraction
DES	Drug-eluting stent	HFrEF	Heart failure with reduced ejection fraction
DEVOTE	Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of cardiovascular Events	HR	Hazard ratio
DIAD	Detection of Ischaemia in Asymptomatic Diabetics	hsTnT	High-sensitivity cardiac troponin T
DIGAMI	Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction	ICA	Invasive coronary angiography
DiRECT	Diabetes Remission Clinical Trial	ICD	Implantable cardioverter defibrillator
DM	Diabetes mellitus	IFG	Impaired fasting glycaemia
DPP4	Dipeptidyl peptidase-4	IGT	Impaired glucose tolerance
DYNAMIT	Do You Need to Assess Myocardial Ischemia in Type 2 Diabetes	IMPROVE-IT	Improved Reduction of Outcomes: Vytorin Efficacy International Trial
EACTS	European Association for Cardio-Thoracic Surgery	J-DOIT3	Japan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular Diseases
EAS	European Atherosclerosis Society	KDIGO	Kidney Disease: Improving Global Outcomes
EASD	European Association for the Study of Diabetes		
ECG	Electrocardiogram		
EDIC	Epidemiology of Diabetes Interventions and Complications		
EET	Exercise electrocardiogram test		
eGFR	Estimated glomerular filtration rate		
ELIXA	Evaluation of Lixisenatide in Acute Coronary Syndrome		
EMPA-REG OUTCOME	Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients – Removing Excess Glucose		
ESC	European Society of Cardiology		

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.